Compare OPAL & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | HOWL |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 64.5M |
| IPO Year | N/A | 2021 |
| Metric | OPAL | HOWL |
|---|---|---|
| Price | $2.69 | $0.65 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $2.81 | ★ $6.50 |
| AVG Volume (30 Days) | 258.7K | ★ 831.2K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $329,243,000.00 | N/A |
| Revenue This Year | $17.15 | N/A |
| Revenue Next Year | $22.04 | N/A |
| P/E Ratio | $118.25 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $1.26 | $0.56 |
| 52 Week High | $4.08 | $2.38 |
| Indicator | OPAL | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 60.50 | 32.32 |
| Support Level | $2.00 | $0.61 |
| Resistance Level | $2.73 | $0.74 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 95.24 | 14.30 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.